A Review of the Cost-Effectiveness and Suitability of Mitigation Strategies to Prevent Phosphorus Loss from Dairy Farms in New Zealand and Australia

2012 ◽  
Vol 41 (3) ◽  
pp. 680-693 ◽  
Author(s):  
Richard W. McDowell ◽  
David Nash
Keyword(s):  
New Zealand ◽  
Cost Effectiveness ◽  
Dairy Farms ◽  
Mitigation Strategies ◽  
Phosphorus Loss ◽  
The Cost

scholarly journals The cost-effectiveness of fluoridating water supplies in New Zealand

2001 ◽  
Vol 25 (2) ◽  
pp. 170-178 ◽  
Author(s):  
Janice C. Wright ◽  
Michael N. Bates ◽  
Terry Cutress ◽  
Martin Lee
Keyword(s):  
New Zealand ◽  
Cost Effectiveness ◽  
Water Supplies ◽  
The Cost

COPY: A new technique for evaluation of biodiversity protection projects

1999 ◽  
Vol 5 (2) ◽  
pp. 115 ◽  
Author(s):  
R. Cullen ◽  
G. A. Fairburn ◽  
K. F. D. Hughey
Keyword(s):  
Invasive Species ◽  
New Zealand ◽  
Cost Effectiveness ◽  
Cost Utility ◽  
Indigenous Species ◽  
Biodiversity Protection ◽  
Output Measure ◽  
Utility Evaluation ◽  
A New Technique ◽  
The Cost

New Zealand, like many other countries, is troubled by introduced animal and plant species which attack, damage, or displace indigenous species. Considerable amounts of taxpayer funds are spent each year attempting to combat these invasive species and some research has been conducted into the "cost effectiveness" and the efficiency of various conservation activities. Research into the cost effectiveness of biodiversity protection projects is hindered by the absence of satisfactory measures of output. A new output measure, Conservation Output Protection Years (COPY) is proposed for use in a cost utility evaluation of biodiversity protection projects. This paper outlines this approach and reports on the use of COPY in evaluation of six New Zealand biodiversity protection projects. The paper demonstrates that COPY provides a practical output measure, and reports on the comparative output per dollar spent on each biodiversity protection project.

The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule

1999 ◽  
Vol 49 (6) ◽  
pp. 763-779 ◽  
Author(s):  
P Scuffham ◽  
N Devlin ◽  
J Eberhart-Phillips ◽  
R Wilson-Salt
Keyword(s):  
New Zealand ◽  
Cost Effectiveness ◽  
Varicella Vaccine ◽  
Immunisation Schedule ◽  
The Cost

The cost effectiveness of universal antenatal screening for HIV in New Zealand

AIDS ◽  
2003 ◽  
Vol 17 (5) ◽  
pp. 741-748 ◽  
Author(s):  
Dale Bramley ◽  
Nicholas Graves ◽  
Damian Walker
Keyword(s):  
New Zealand ◽  
Cost Effectiveness ◽  
Antenatal Screening ◽  
The Cost

Cost-effectiveness of a cervical screening program with human papillomavirus vaccine

2011 ◽  
Vol 27 (4) ◽  
pp. 290-297 ◽  
Author(s):  
Elizaveta Sopina ◽  
Toni Ashton
Keyword(s):  
Human Papillomavirus ◽  
New Zealand ◽  
Cost Effectiveness ◽  
Hpv Vaccine ◽  
Screening Program ◽  
Cervical Screening ◽  
Screening Strategy ◽  
Vaccine Uptake ◽  
Screening Strategies ◽  
The Cost

Objectives: Recent introduction of a quadrivalent human papillomavirus (HPV) vaccine for girls in New Zealand is expected to decrease the incidence of HPV infection as well as resultant cytological abnormalities and cervical cancer. This may affect the cost-effectiveness of the national cervical screening program by reducing the incidence of lesions detected. This study investigates the cost-effectiveness of the current cervical screening policy with and without the HPV vaccine and compares these results with the cost-effectiveness of a range of other screening strategies.Methods: A Markov state-transition model was built based on the natural history of HPV and cervical carcinogenesis. The model followed a hypothetical cohort of girls from 12 years to 85 years of age or death, through screening and treatment pathways. The model compared a “no vaccine and current screening” strategy with a selection of screening strategies with different age ranges and frequency intervals.Results: The most cost-effective cervical screening strategy in the presence of the HPV vaccine would be screening women aged 30–60 every 5 years. Moving to this screening strategy from the base case of no vaccine and the current New Zealand strategy of screening women aged 20–69 every 3 years is predicted to have an incremental cost per quality-adjusted life-year gained of NZ$9,841 (€4,428).Conclusions: Reducing screening intensity from 3 to 5 years as well as narrowing the screening age range for the vaccinated cohort once they reach mid-twenties is recommended. The importance of achieving a high vaccine uptake in New Zealand remains high.

Sign in / Sign up

Export Citation Format

Share Document